GoodRx price target raised to $10 from $9 at Barclays

Barclays raised the firm’s price target on GoodRx to $10 from $9 and keeps an Overweight rating on the shares. The firm says its lunch with management highlighted the evolution of GoodRx’s business model from pharmacy benefits manager cash pay arbitrage to a retail pharmacy enabler with opportunities in linking pharma brands to the consumer. The analyst is now incrementally more positive on the shares.